Related Experiment Video

Updated: Aug 9, 2026

Utilizing an Orally Dissolving Strip for Pharmacological and Toxicological Studies: A Simple and Humane Alternative to Oral Gavage for Animals
04:28

Utilizing an Orally Dissolving Strip for Pharmacological and Toxicological Studies: A Simple and Humane Alternative to Oral Gavage for Animals

Published on: March 23, 2016

Methylphenidate (OROS formulation)

G M Keating1, K McClellan, B Jarvis

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

CNS Drugs
|August 29, 2001
PubMed

Insights

This study shows that the OROS methylphenidate formulation effectively treats attention deficit/hyperactivity disorder (ADHD) in children. Once-daily OROS methylphenidate demonstrated sustained efficacy and a similar tolerability profile to immediate-release methylphenidate.

Area of Science:

  • Pharmacology
  • Neuroscience
  • Pediatrics

Background:

  • Methylphenidate is a central nervous system stimulant.
  • It is believed to inhibit dopamine and noradrenaline reuptake.
  • The OROS formulation offers sustained release for attention deficit/hyperactivity disorder (ADHD).

Purpose of the Study:

  • To evaluate the efficacy and tolerability of OROS methylphenidate in children with ADHD.
  • To compare the pharmacokinetic profile of OROS methylphenidate in children and adults.
  • To assess the long-term efficacy of OROS methylphenidate.

Main Methods:

  • A clinical trial involving 282 children with ADHD.
  • Administration of once-daily OROS methylphenidate (18-54 mg) or placebo.
  • Comparison with immediate-release (IR) methylphenidate (5-15 mg 3 times daily).
  • A 1-year noncomparative study for sustained efficacy assessment.

Main Results:

  • Once-daily OROS methylphenidate was significantly more effective than placebo in reducing ADHD symptoms.
  • OROS methylphenidate showed efficacy comparable to IR methylphenidate.
  • The OROS formulation exhibited sustained efficacy over 1 year.
  • Pharmacokinetic profiles differed between OROS methylphenidate and other formulations in adults.

Conclusions:

  • OROS methylphenidate is an effective and well-tolerated treatment for pediatric ADHD.
  • The sustained-release formulation provides a convenient once-daily dosing option.
  • OROS methylphenidate demonstrates comparable efficacy and tolerability to immediate-release methylphenidate.

More Related Videos

Color Spot Test As a Presumptive Tool for the Rapid Detection of Synthetic Cathinones06:06

Color Spot Test As a Presumptive Tool for the Rapid Detection of Synthetic Cathinones

Published on: February 5, 2018

Studying Metabolic Brain Connectivity Using 2-Deoxy-2-[18F]Fluoro-D-Glucose Dynamic Positron Emission Tomography at the Single-subject Level07:28

Studying Metabolic Brain Connectivity Using 2-Deoxy-2-[18F]Fluoro-D-Glucose Dynamic Positron Emission Tomography at the Single-subject Level

Published on: January 24, 2025

Related Concept Videos

Adrenergic Agonists: Direct-Acting Agents01:30

Adrenergic Agonists: Direct-Acting Agents

Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
Adrenergic Agonists: Mixed-Action Agents01:28

Adrenergic Agonists: Mixed-Action Agents

Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Antiasthma Drugs: Methylxanthines01:24

Antiasthma Drugs: Methylxanthines

Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Drug Delivery Systems: Different Types01:27

Drug Delivery Systems: Different Types

Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...